We used a herpes simplex virus (HSV) type 1 ribonucleotide reductase (RR) null mutant (ICP6A) to study the role of HSV-1 RR in ocular HSV infections. We found that ICP6A was unable to induce vascularization of the cornea or stromal keratitis following inoculation into the cornea of BALB/c mice, but was able to induce a transient mild blepharitis. The parental strain (HSV-1 KOS) and a revertant ofICP6A, ICP6A ÷ 3.1, both caused severe ocular disease, indicating that HSV-1 RR is required for ocular virulence in mice.
Introduction
Herpes simplex virus (HSV) types 1 and 2 both encode the enzyme ribonucleotide reductase (RR, EC 1.17.4.1), which is composed of two non-identical subunits (Ponce de Leon et al., 1977; Huszar & Bacchetti, 1981 : Dutia, 1983 Bacchetti et al., 1984; Preston et al., 1984; Frame et al., 1985) . The large subunit (Mr 140000), designated ICP6 (Honess & Roizman, 1973 , 1974 , is encoded by the UL39 gene; the small subunit (M~ 38000) is encoded by the UL40 gene (McGeoch et al., 1988) . These genes map between 0.562 and 0.597 map units on the viral genome and are translated from 3'-coterminal mRNAs of 5-0 and 1-2 kb respectively (Anderson et al., 1981; McLauchlan & Clements, 1983; Swain & Galloway, 1986) . The structure of this region of the HSV genome is shown schematically in Fig. 1 .
RR reduces ribonucleotides to the corresponding deoxyribonucleotides and is essential for the formation of substrates for DNA synthesis (reviewed in Thelander & Reichard, 1979) . The importance of RR is emphasized by the presence of similar enzymes in organisms as diverse as Escherichia coli (Carlson et al., 1984) , mice (Caras et al., 1985) and humans (Frenkel et al., 1964) , as well as Epstein-Barr virus (Henry et al., 1978) , pseudorabies virus (Lankinen et al., 1982) , equine herpesvirus type 1 and vaccinia virus (Child et al., 1990) .
Despite the essential role of RR in DNA synthesis, recent studies have shown that the HSV-encoded RR is not necessary for growth in certain cultured cells (Goldstein & Weller, 1988; Preston et al., 1988 ), suggesting that the host cell RR can substitute for the viral enzyme. This conclusion is supported by the observation that RR mutants show reduced growth under conditions in which host cell RR activity is low (e.g. conditions of serum starvation; Goldstein & Weller, 1988) .
Viral enzymes that use nucleosides or nucleotides as substrates have proven to be effective targets for antiviral drug development, and RR has attracted interest as a potential target (Spector, 1985; Dutia et al., 1986; Cohen et al., 1986) . However, if RR is not essential for growth, antiviral drugs that inhibit RR activity may not be effective. Mutants that fail to express RR make it possible to determine whether RR is required for growth and, more importantly, virulence in an animal host. Recently, Cameron et al. (1988) have reported that the mutant ts1222 is avirulent in albino Charles River mice. Following intraperitoneal or intracerebral inoculation, ts1222 has an LDs0 value 6 to 7 log units higher than that of the 17 syn + parent. However, Cameron et al. (1988) did not determine whether the reduced virulence resulted from reduced capacity to grow in mice. Jacobson et al. (1989) have shown that the RR deletion mutant ICP6A shows reduced ability to replicate following peripheral 0001-0045 © 1991 SGM ( o c u l a r ) i n o c u l a t i o n i n t o C D -I m i c e a n d is u n a b l e to e s t a b l i s h r e a c t i v a t a b l e l a t e n t i n f e c t i o n s .
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Methods
Cell cultures. African green monkey kidney cells (Vero) and BALB/c 3T3 fibroblasts were grown in Dulbecco's modification of Eagle's medium (DMEM) containing 5% serum [1:1 v/v mixture of foetal bovine serum (FBS) and defined supplemented calf serum; Hyclone], 100 units/ml penicillin and 100 gg/ml streptomycin sulphate. Primary human corneal fibroblast (PHCF) cultures were established by mincing normal donor corneas, placing them in 60 mm culture dishes containing Ham's F12 medium with 10% FBS, 10 mM-HEPES pH 7.2 and antibiotics as described above, and incubating at 37 °C with 5% CO2. After 2 weeks the cells were trypsinized, transferred to a 100 mm dish and subsequently passaged (split 1 : 3) each week. All experiments were carried out in cells at passage 5 or 6. Informed consent was obtained for the use of the donor corneas.
Viruses. The RR deletion mutant (ICP6A) and the revertant (ICP6A÷3.1) have been described previously (Goldstein & Weller, 1988) and were derived from HSV-1 KOS. ICP6A carries a 2.9 kb deletion that removes 90% of the coding region of the large subunit (ICP6) of RR, including the initiation codon. The revertant ICP6A÷3.1 was isolated after marker rescue of 1CP6A with the cloned HpaI F fragment of HSV-I KOS. Fig. 1 shows a schematic diagram of the HSV-1 genome, including the location of the genes encoding RR, the position of the deletion in ICP6A and the location of the HpaI F fragment used to rescue ICP6A. High titre stocks of virus were prepared in Vero cells as previously described (Grau et al., 1989) .
Animal inoculation and disease scoring. Female BALBJc mice (4 to 6 weeks old) were purchased from Harlan Sprague Dawley and infected with an inoculum of 1-0 x 105 p.f.u, of virus in 5 gl of DMEM containing 2% serum, using the eye scratch method described previously (Grau et al., 1989) . The number of animals infected with each virus is shown in Table 1 . Methods for scoring stromal keratitis, vascularization of the cornea and blepharitis, including mean peak disease scores (MPDS), have been described previously (Grau et aL, 1989; Brandt & Grau, 1990) . All animal experiments were carried out according to National Institutes of Health (NIH) and Association for Research and Vision in Ophthalmology (ARVO) guidelines. 0 0-1 0-2 0-3 0.4 0.5 0-6 0-7 0.8 0.9 1.0 I  I  I  I  I  I  I  I  I  I 
Schematic diagram showing the location of the regions encoding the large and small subunits of HSV-I RR. The location of the 2-9 kb deletion in the HpaI F fragment used to construct the ICP6A mutant is shown below the expanded restriction map. The Hpal F fragment used to rescue the ICP6A mutant is shown on the bottom line.
In vivo growth curves. At various times after ocular infection, mice were killed, and the eyes, trigeminal ganglia (TG) and brains were removed aseptically and stored at -80 °C prior to assay for infectious virus. The eyes and TG were homogenized in 600 gl DMEM containing 2% serum, frozen and thawed three times, centrifuged at 1000 r.p.m. for 5 min and the supernatants were titrated onto Vero cells. Brains were treated similarly except that they were resuspended in a volume of 2.0 ml. Three tissues were titrated at each time point with the exception of day 8, when the brains from six animals were used for titration.
In vitro growth curves. Cells were infected at a multiplicity of 2 p.f.u. virus/cell in medium containing 2% serum. At various times postinfection (p.i.), the cells were harvested and stored at -8 0 °C. After all samples had been collected, they were frozen and thawed three times, centrifuged at 1000 r.p.m, for 5 min and titrated onto Vero cells.
Reactivation from latency. Mice infected with 1 × 105 p.f.u, of either ICP6A, ICP6A+3.1 or HSV-1 KOS were kept for 30 days p.i. At that time, the cornea, TG and brain were aseptically removed; one-half of the samples were homogenized, frozen and thawed three times, and titrated for infectious virus, whereas the remaining samples were minced, placed in DMEM containing 5% serum and fungizone (5 gg/ml), and incubated at 37 °C. Samples of cornea and TG were incubated in a volume of 1.5 ml and brains in 2.0 ml. Every 2 to 3 days for 2 weeks the medium was replaced and the harvested medium tested for the presence of infectious virus by plating on Vero cells.
Statistical analysis. MPDSs were analysed by ANOVA using Statview 521 + software. Statistically significant differences for disease scores of each virus were calculated at the 95 % significance level using Fisher's protected least significant difference (PLSD) and Scheffe's F tests. The wild-type parent, HSV-1 KOS, and the revertant, ICP6A+3.1, both caused severe blepharitis. Eyelid inflammation was first visible on day 3, peaked between days 7 and 9 (score of 3.0) and then began to clear, but was still present on day 15 (score 1.5 to 2.0), when scoring was ended. In contrast, the RR deletion mutant (ICP6A) caused little eyelid inflammation; slight swelling was noticed on days 3 and 5 (score 0-25), but had cleared by day 7.
Results

Kinetics o f ocular disease
Vascularization induced by HSV-I KOS was observed on days 3 to 5 and increased steadily until day 15, when scoring ended. Vascularization induced by ICP6A+3.1 was not observed until day 9, but increased rapidly, peaking at a score of 1.7 on day 15. Vascularization of the cornea was never seen in mice infected with ICP6A. Stromal keratitis was observed beginning on day 9 in animals infected with HSV-1 KOS, and increased to a score of 2.0 to 2.15 on days 12 and 15. ICP6A+3.1 induced stromat keratitis which was first observed on day 9, and increased to a score of 2.7 to 2.8 on days 12 and 15. The ICP6A mutant failed to induce stromal keratitis.
The reduced ability of ICP6A to cause severe ocular disease is also reflected in the MPDSs (Fig. 3) . Statistical analysis of the MPDSs indicated that the blepharitis, vascularization of the cornea and stromal keratitis caused by HSV-I KOS and ICP6A+3.1 were not significantly different from each other, but were significantly more severe (P < 0.05) than the disease caused by ICP6A.
The reduced virulence of ICP6A was also reflected in the percentage of animals that showed evidence of ocular disease (Table 1) . All the animals infected with HSV-1 KOS and ICP6A+3.1 developed blepharitis, compared to 36.4~ of the animals infected with ICP6A. HSV-1 KOS and ICP6A+3.1 induced corneal vascularization in over 77 ~ of infected mice; none of the ICP6A-infected animals developed vascularization. Similar results were seen for stromal keratitis, 81.8 ~o and 80~o of the animals infected with HSV-1 KOS and ICP6A+3.1, respectively, showed disease, whereas none of the ICP6A-infected animals did.
Growth in vivo
The avirulence of ICP6A could result from a number of factors including failure to grow in vivo. To determine whether ICP6A was able to replicate in vivo, we infected mice with each of the viruses, and removed the cornea, TG and brain, and titrated the infectious virus 1,2, 3, 6, 8 and 10 days p.i. (Fig. 4) . The titre of HSV-1 KOS and ICP6A÷3.1 in the cornea peaked on day 1 p.i. and declined thereafter, but were approximately 1.5 log units higher than peak corneal titres of ICP6A. HSV-I KOS and ICP6A+3.1 titres peaked on day 5 p.i. in the TG, whereas ICP6A was not detected at any time. Brain titres peaked on day 5 p.i. in animals infected with HSV-1 KOS or ICP6A÷3.1 ; we were unable to detect any ICP6A in the brains of infected animals. The titre of HSV-1 KOS in the brain dropped to very low levels on days 8 and 10 p.i. whereas the titre of ICP6A+3.1 in the brain of infected animals remained high (Fig. 4) . The significance of this is not clear because only one of six mice had virus in the brain at day 8 and only one of three on day 10.
In vitro growth
The results of studies on the ability of the viruses to grow in mice showed that ICP6A was impaired in its ability to grow and suggested that the avirulence of ICP6A is a result of this inability to grow. These results also show that RR is required for virulence in the mouse. To establish whether there was an association between growth in vivo, ability to cause disease, and the ability to grow in vitro, we determined the growth characteristics in BALB/c 3T3 fibroblasts. We found that HSV-1 KOS and ICP6A+3.1 grew equally well in these cells (Fig. 5 ). ICP6A did not grow as well, its titre was between 1 and 1.5 log units lower than those of HSV-1 KOS and ICP6A+3.1 at 24 h p.i., and 2 log units lower at 44 h p.i. These results show that there is a relationship between the in vivo and in vitro growth characteristics in the murine system. We also found that HSV-1 KOS and ICP6A+3.1 grew equally well in Vero cells, but ICP6A grew to a peak titre approximately 1.5 log units lower (Fig. 5) . These results are similar to those reported by Goldstein & Weller (1988) .
To determine whether RR could be a virulence factor in humans, we looked at growth in PHCFs (Fig. 5 ). HSV-1 KOS and ICP6A+3.1 grew equally well in PHCFs, reaching peak titres of approximately 8 log units; in contrast, ICP6A grew less well, reaching a peak titre of approximately 6 log units. Since the requirement for viral RR is dependent on temperature (Goldstein & Weller, 1988; Preston et al., 1988) , we also carried out single-step growth curve experiments in PHCFs at 39 °C (Fig. 5 ). All three viruses grew poorly at 39 °C. We cannot, therefore, conclude that the growth of the RR-deficient virus is more impaired at 39 °C than that of either the HSV-1 KOS parent or the ICP6A+3.1 revertant. The titre of HSV-I KOS was significantly higher than those of ICP6A or ICP6A+3.1 at 48 h (P < 0.05), but as we did not continue the growth curves beyond 48 h the significance of this rise in titre is not known. The cornea is normally slightly below internal body temperature and corneal cells themselves may therefore be somewhat temperature-sensitive. If so, this could affect the growth of all the viruses tested. 
Reactivation from latency
Reactivation of latent ocular infections can result in increasingly severe stromal keratitis in humans. Therefore we tested HSV-1 KOS, ICP6A÷3.1 and ICP6A for their ability to reactivate from latency. Infected animals were killed 1 month p.i. and the cornea, TG and brain were removed. Half of the samples were tested for infectious virus and half were tested for latency; the results are shown in Table 2 . We found no evidence for latent virus in the cornea or brain of any of the mice. All of the TG samples from mice infected with HSV-1 KOS and ICP6A÷3.1 were positive for reactivation; none of the TGs from animals infected with ICP6A was positive.
Discussion
The ICP6A null mutant was unable to cause stromal keratitis or induce vascularization of the cornea in infected animals and caused only minimal blepharitis, whereas the revertant, ICP6A+3.1, caused blepharitis, vascularization and stromal keratitis as severe as that of the HSV-1 KOS parent. These results demonstrate that HSV-I RR is required for the development of severe ocular disease in mice and that the avirulence of ICP6A is not due to a mutation elsewhere in the viral genome because recombining the RR gene back into ICP6A restored virulence. The reduced ocular virulence of ICP6A is most likely to result from poor replication in the cornea. We found that the peak titre of ICP6A in the cornea was approximately 1 log unit lower than that of HSV-1 KOS or ICP6A+3.1, and peaked 1 day later. Our results are similar to those of Jacobson et al. (1989) , who found that ICP6A replicated poorly in vivo.
We also found that ICP6A was defective in reactivation and/or establishment of latency in BALB/c mice; similar results were reported by Jacobson et al. (1989) using CD-1 mice. Together, these results suggest that the defect in latency is not specific for the strain of mouse. ICP6A DNA is present at levels 50-fold lower than those of wild-type HSV-1 KOS DNA in the TG of latently infected mice, suggesting that RR is required for reactivation but not establishment of latency (Katz et al., 1990) .
Our results, and the results of Cameron et al. (1988) , contrast with results reported recently using guinea-pigs (Turk et al., 1990) in which mutant viruses lacking RR (LrR3 and ICP6A) were able to cause ulcerative lesions following skin inoculation. The reasons for these differences in virulence are not clear although guinea-pig RR could be a more effective substitute for the viral enzyme than mouse RR. The difference in virulence could also be related to the route of inoculation (e.g. skin rather than cornea and brain), although this seems unlikely since we and others (Turk et al., 1990; Jacobson et al., 1990) have shown that ICP6A replicates poorly in mouse fibroblasts in vitro. It is also possible that skin cells divide more rapidly than cells in the cornea or brain and therefore contain higher levels of RR. Finally, there could be some other unknown species difference. The inability of ICP6A to grow in mice does not appear to be strain-specific because ICP6A has now been shown to grow poorly in CD-1 and BALB/c mice.
Based on our results, RR appears to be a logical target for development of antiviral drugs to treat ocular HSV infections. However, the ability of RR null mutants to cause lesions in guinea-pigs (Turk et al., 1990) suggests species differences exist and, although RR is required for virulence in mice, it may not be as essential in human infections. However, we carried out one-step growth curves in PHCFs and found that ICP6A grew to a peak titre 2 log units lower than HSV-1 KOS and ICP6A+3.1. This result, together with the demonstration of an association between replication in BALB/c 3T3 fibroblasts, replication in vivo and the severity of ocular disease, suggests that RR may be required for ocular virulence in humans. ICP6A also replicates poorly in human foreskin fibroblasts and human lung carcinoma cells (A549; Goldstein & Weller, 1988; Turk et al., 1989 ), suggesting that the requirement for RR in humans is not cell type-specific.
In summary, our results show that RR is required for ocular virulence in mice, probably as a result of reduced capacity to grow in the absence of the viral enzyme, and that RR is likely to be required for virulence in humans, suggesting that inhibitors of HSV RR will be worth testing for their therapeutic value in treating ocular HSV infections.
